We are live on ! Find out more
DCOY

Decoy Therapeutics
DCOY

7 hedge funds and large institutions have $186K invested in Decoy Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more funds holding

Funds holding: 4 → 7 (+3)

68% more capital invested

Capital invested by funds: $111K → $186K (+$75.1K)

0% more ownership

Funds ownership: 0% → 0% (+0%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
7
Holders Change
+3
Holders Change %
+75%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HKAM
Horizon Kinetics Asset Management
New York
+$74K
2
Two Sigma Investments
Two Sigma Investments
New York
+$22.5K
3
Renaissance Technologies
Renaissance Technologies
New York
+$9.65K
4
UBS Group
UBS Group
Switzerland
+$3.22K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$48.3K

DCOY Hedge Fund Activity: Q1 2023 in Review

7 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q1 2023, worth a combined $186K — up 68% from $111K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new DCOY positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Horizon Kinetics Asset Management, opening a new position worth an estimated $74K. The largest seller was Vanguard Group, cutting an estimated $48.3K.

  • 7 institutional investors held Decoy Therapeutics (DCOY) as of Q1 2023, up from 4 in Q4 2022.
  • Funds reported $186K of Decoy Therapeutics stock for Q1 2023, up 68% quarter-over-quarter.
  • 3 funds opened new Decoy Therapeutics positions in Q1 2023 and 0 closed out, a net change of +3 holders.
  • The largest Decoy Therapeutics buyer in Q1 2023 was Horizon Kinetics Asset Management, an estimated $74K added.
  • The largest Decoy Therapeutics seller in Q1 2023 was Vanguard Group, an estimated $48.3K sold.

Based on aggregated 13F filings for Q1 2023.